119 related articles for article (PubMed ID: 2147952)
1. Altered erythrocyte CR1 binding kinetics compensate for decreased binding capacity in rheumatoid arthritis.
Hargrove JK; Meryhew NL; Runquist OA
J Clin Chem Clin Biochem; 1990 Aug; 28(8):533-41. PubMed ID: 2147952
[TBL] [Abstract][Full Text] [Related]
2. A kinetic study of erythrocyte-DNA/anti-DNA immune complex association and dissociation reactions in systemic lupus erythematosus.
Meryhew NL; Westling PR; Eerdmans ME; Janecek EJ; Runquist OA
Biochim Biophys Acta; 1989 Jun; 991(3):470-6. PubMed ID: 2786431
[TBL] [Abstract][Full Text] [Related]
3. Immune complex binding efficiency of erythrocyte complement receptor 1 (CR1).
Madi N; Paccaud JP; Steiger G; Schifferli JA
Clin Exp Immunol; 1991 Apr; 84(1):9-15. PubMed ID: 1826650
[TBL] [Abstract][Full Text] [Related]
4. Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions.
Ng YC; Schifferli JA; Walport MJ
Clin Exp Immunol; 1988 Mar; 71(3):481-5. PubMed ID: 2968204
[TBL] [Abstract][Full Text] [Related]
5. In vivo binding of circulating immune complexes by C3b receptors (CR1) of transfused erythrocytes.
Inada Y; Kamiyama M; Kanemitsu T; Ikegami H; Watanabe K; Clark WS; Asai Y
Ann Rheum Dis; 1989 Apr; 48(4):287-94. PubMed ID: 2523692
[TBL] [Abstract][Full Text] [Related]
6. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
[TBL] [Abstract][Full Text] [Related]
7. Immune complexes bind preferentially to specific subpopulations of human erythrocytes.
Cosio FG; Shen XP; Hebert LA
Clin Immunol Immunopathol; 1990 Jun; 55(3):337-54. PubMed ID: 2140304
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of C3b receptor (CR1) on erythrocytes of patients with systemic lupus erythematosus contrasts with its normal expression in other systemic diseases and does not correlate with the occurrence or severity of SLE nephritis.
Jouvin MH; Wilson JG; Bourgeois P; Fearon DT; Kazatchkine MD
Complement; 1986; 3(2):88-96. PubMed ID: 2945697
[TBL] [Abstract][Full Text] [Related]
9. Difference in the clustering of complement receptor type 1 (CR1) on polymorphonuclear leukocytes and erythrocytes: effect on immune adherence.
Paccaud JP; Carpentier JL; Schifferli JA
Eur J Immunol; 1990 Feb; 20(2):283-9. PubMed ID: 2138082
[TBL] [Abstract][Full Text] [Related]
10. The change in C3b receptors on erythrocytes from patients with systemic lupus erythematosus.
Yoshida K; Yukiyama Y; Hirose S; Miyamoto T
Clin Exp Immunol; 1985 Jun; 60(3):613-21. PubMed ID: 3160514
[TBL] [Abstract][Full Text] [Related]
11. The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans.
Schifferli JA; Ng YC; Paccaud JP; Walport MJ
Clin Exp Immunol; 1989 Mar; 75(3):329-35. PubMed ID: 2522842
[TBL] [Abstract][Full Text] [Related]
12. Erythrocyte complement receptor type 1 in non-SLE rheumatic diseases.
Yen JH; Liu HW; Lin SF; Chen TP
Rheumatol Int; 1990; 10(2):71-3. PubMed ID: 2349436
[TBL] [Abstract][Full Text] [Related]
13. Low number of complement C3b/C4b receptors (CR1) on erythrocytes from patients with essential mixed cryoglobulinemia, systemic lupus erythematosus and rheumatoid arthritis: relationship with disease activity, anticardiolipin antibodies, complement activation and therapy.
Corvetta A; Pomponio G; Bencivenga R; Luchetti MM; Spycher M; Spaeth PJ; Danieli G
J Rheumatol; 1991 Jul; 18(7):1021-5. PubMed ID: 1833542
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analyses of the binding of soluble complement-fixing antibody/dsDNA immune complexes to CR1 on human red blood cells.
Edberg JC; Wright E; Taylor RP
J Immunol; 1987 Dec; 139(11):3739-47. PubMed ID: 2960742
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates.
Cosio FG; Shen XP; Birmingham DJ; Van Aman M; Hebert LA
J Immunol; 1990 Dec; 145(12):4198-206. PubMed ID: 2147938
[TBL] [Abstract][Full Text] [Related]
16. Binding of model immune complexes to erythrocyte CR1 facilitates immune complex uptake by U937 cells.
Emlen W; Burdick G; Carl V; Lachmann PJ
J Immunol; 1989 Jun; 142(12):4366-71. PubMed ID: 2524529
[TBL] [Abstract][Full Text] [Related]
17. Release of immune complexes bound to erythrocyte complement receptor (CR1), with particular reference to the role of factor I.
Jepsen HH; Svehag SE; Jensenius JC; Sim RB
Scand J Immunol; 1986 Aug; 24(2):205-13. PubMed ID: 2944215
[TBL] [Abstract][Full Text] [Related]
18. Erythrocytes from young but not elderly donors can bind and degrade immune complex- and antibody-bound C3 in vitro.
Shapiro S; Kohn D; Miller B; Gershon H
Clin Exp Immunol; 1994 Jan; 95(1):181-90. PubMed ID: 8287603
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing the binding of large immune complexes to the primate erythrocyte CR1 receptor.
Cornacoff JB; Hebert LA; Birmingham DJ; Waxman FJ
Clin Immunol Immunopathol; 1984 Feb; 30(2):255-64. PubMed ID: 6692603
[TBL] [Abstract][Full Text] [Related]
20. Influence of processing by erythrocyte C3b/C4b receptors (CR1) on binding of immune complexes to Raji cells and polymorphonuclear granulocytes.
Rasmussen JM; Jepsen HH; Svehag SE
Scand J Immunol; 1987 Oct; 26(4):437-44. PubMed ID: 2961050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
